GBT Announces New Employment Inducement GrantsHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)GBT Announces New Employment Inducement GrantsGlobeNewswireJanuary 8, 2020ReblogShareTweetShareSOUTH SAN FRANCISCO, Calif., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (GBT) today announced that on January 1, 2020, the compensation committee of GBT’s board of directors granted 7 new employees options to purchase an aggregate of 11,200 shares of the company’s common stock with a per share exercise price of $79.49 and restricted stock units for an aggregate of 24,900 shares of the company’s common stock. All of the above-described awards were made under the GBT’s Amended and Restated 2017 Inducement Equity Plan (the Plan). Pursuant to the Plan, the exercise price for the 11,200 shares of the Company’s common stock was the closing trading price on December 31, 2019, because there was no closing trading price on January 1, 2020.The above-described awards were each granted as an inducement material to the employees entering into employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was adopted by GBT’s board of directors in January 2017.About Global Blood TherapeuticsGBT is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta™ (voxelotor), the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a p-selectin inhibitor in development to address pain crises associated with the disease. In addition, GBT’s drug discovery teams are working on new targets to develop the next generation of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.Contact Information:Steven Immergut (media)GBT650-410-3258media@gbt.comStephanie Yao (investors)GBT650-741-7730investor@gbt.comReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextAllied Esports withdraws planned public offeringAmerican City Business JournalsA new calculator sheds light on high-flying U.S. unicorn price tagsReutersPublic Storage (PSA) Q4 FFO & Revenues Miss Estimates, Up Y/YZacksBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoMost face masks won’t protect you from the coronavirusYahoo Finance'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo FinancePersonal loans growth rate rises, impacts retailersYahoo Finance Video